Phenotyping and genotyping of CYP2C19 using comparative metabolism of proguanil in sickle‐cell disease patients and healthy controls in Nigeria

• Published in: Pharmacology research & perspectives Vol. 4; no. 5; pp. e00252 - n/a
• Main Authors: Adejumo, Olufunmilayo E., Kotila, Taiwo R., Falusi, Adeyinka G., Silva, Boladale O., Nwogu, Jacinta N., Fasinu, Pius S., Babalola, Chinedum P.
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.10.2016; John Wiley and Sons Inc
• Subjects: Chromatography; CYP2C19; Dihydrofolate reductase; Drug dosages; Enzymes; Family medical history; genetic polymorphism; Genotype & phenotype; Malaria; Metabolism; Metabolites; Mutation; Original; Patients; Pediatrics; Pharmacology; Polymorphism; Population; proguanil; Sickle cell disease; Nigeria; proguanil; sickle‐cell disease; CYP2C19; genetic polymorphism
• ISSN: 2052-1707; 2052-1707
• DOI: 10.1002/prp2.252

Polymorphic expression of metabolic enzymes have been identified as one of the key factors responsible for the interindividual/ethnic/racial variability in drug metabolism and effect. In Nigeria, there is a disproportionately high incidence of sickle‐cell disease (SCD), a condition characterized by painful crisis frequently triggered by malaria. Proguanil, a substrate of the polymorphic CYP2C19, is a chemoprophylactic antimalarial drug widely used among SCD patients in Nigeria. This study aimed to conduct a comparative CYP2C19 phenotyping among SCD patients and healthy controls and to compare the results with those previously reported. One hundred seventy‐seven unrelated subjects comprising 131 SCD patients and 46 non‐SCD volunteers were phenotyped. This was carried out by collecting pooled urine samples over 8 h following PG administration. Proguanil and its major CYP2C19‐dependent metabolites were measured by high‐performance liquid chromatography. Metabolic ratios (MRs) were computed and employed in classifying subjects into poor or extensive metabolizers. Among SCD group, 130 (99.2%) were extensive metabolizers (EMs) and 1 (0.8%) was poor metabolizer (PM) of PG, while 95.7 and 4.3% non‐SCDs were EMs and PMs, respectively. MRs ranged from 0.02 to 8.70 for SCD EMs and from 0.22 to 8.33 for non‐SCD EMs. Two non‐SCDs with MRs of 18.18 and 25.76 and the SCD with MR of 16.77 regarded as PMs had earlier been genotyped as CYP2C19*2/*2. Poor metabolizers of proguanil in SCD patients are reported for the first time. Regardless of clinical significance, a difference in metabolic disposition of proguanil and CYP2C19 by SCDs and non‐SCDs was established.